A61K9/107

Topical treatment for anorectal disorders with and without seat cushion
11576801 · 2023-02-14 ·

A topical treatment for anorectal disorders with and without utilization of a contoured seat cushion with a temperature-adapted or electrical stimulation element that can provide hot or cold temperatures or electrical stimulation to the anorectal region.

PHOSPHATE DERIVATIVES OF RORGAMMA MODULATORS AND USES THEREOF

The present invention relates to phosphate derivatives of formula (I), and their therapeutic uses, preferably for treating a respiratory disease. The present invention further relates to pharmaceutical compositions and devices comprising such compounds.

PARENTERAL LYSOPHOSPHATIDYLCHOLINE FORMULATIONS SUCH AS LPC-DHA, LPC-EPA AND THEIR USE IN THERAPY

The present invention relates to pharmaceutical formulations of phospholipids, and in particular pharmaceutical formulations which are administered intravascularly such as intravenously. In particular, the present invention provides pharmaceutical compositions for intravascular administration comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy.

TOPICAL COMPOSITION COMPRISING TOFACITINIB AND FINGOLIMOD
20230037905 · 2023-02-09 ·

The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, and eczema.

TOPICAL COMPOSITION COMPRISING TOFACITINIB AND FINGOLIMOD
20230037905 · 2023-02-09 ·

The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, and eczema.

ALKYLATED NUCLEOSIDES, AND COMPOSITIONS AND METHODS THEREOF FOR NUCLEIC ACID DELIVERY

The invention provides novel compounds, compositions and formulations of liposomes, microbubbles and/or nanodroplets, and emulsions thereof, that are useful in delivery of various nucleic acids and genes (e.g., single stranded RNA, DNA, si-RNA and CRISPR constructs), as well as methods of preparation and use thereof including methods of imaging and gene delivery using ultrasound activation.

Sleep quality using full spectrum hemp oil
20230038771 · 2023-02-09 ·

This disclosure provides cannabinoid preparations for human consumption that have proven clinical benefits in patients infected with SARS-CoV-2 (the virus that causes COVID-19). The preparations are made from full-spectrum hemp oil, which includes a mixture of cannabinoids that work synergistically. The hemp oil is micellized with a median particle size of 22 nm in diameter, which considerably increases intestinal absorption, resulting in higher potency and a more rapid onset of action. Taken regularly, the preparation helps improve sleep quality by lengthening the time spent in deep sleep. In patients with COVID, the improved sleep quality is accompanied by a lower risk of cytokine storm.

Chemotherapeutic self-nanoemulsifying drug delivery systems and uses thereof

Self-nanoemulsifying drug delivery system (SNEDDS) composition are provided. The compositions include at least one chemotherapeutic compound or a pharmaceutically acceptable salt thereof or mixture thereof, at least one biocompatible surfactant, wherein the at least one biocompatible surfactant includes surfactin, and at least one co-surfactant. Methods of enhancing the bioavailability of the chemotherapeutic compound and for treating cancer are also provided.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.

Ruxolitinib formulation for reduction of itch in atopic dermatitis

This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.